Palo Alto-based Finjan (NASDAQ: FNJN), established over 20 years ago, is a globally recognized pioneer in cybersecurity. Finjan's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation.

Finjan Mobile is committed to incorporating Finjan's enterprise-grade technology into products that increase Internet security for our customers using mobile devices. Finjan Mobile listens to customer's feedback, innovates in response to that feedback and new challenges, and looks for both organic and inorganic paths towards future growth.

Finjan Blue, Inc., a wholly owned subsidiary of Finjan Holdings, has entered into a patent acquisition and development agreement with IBM, and includes pathways for the two companies to consider development efforts in the future. The Agreement, the terms of which are confidential, includes the transfer of select security-related patent assets and provides for the sharing of pertinent institutional knowledge and resources by IBM to Finjan Blue.

Finjan Mobile’s most recent launch is the InvinciBull VPN Browser which is built-off Finjan’s patented technology. InvinciBull is the only mobile app to integrate a VPN with a secure, feature-rich browser. The Virtual Private Network (VPN) keeps consumers data safe by encrypting all internet traffic when using public Wifi in a coffee shop, hotel or airport hotspot.

Finjan, founded in 1996, is a diversified technology company.  Finjan's engineers and developers pioneered behavior-based, real-time detection of online threats, and the company's patents cover core functionality and features used in modern security architectures.  Finjan operates four distinct business units:

• An IP licensing business leverages a host of patents through its subsidiaries Finjan, Inc, Finjan Mobile and Finjan Blue.

• The VitalSecurity™ platform protects consumer mobile devices in the workplace while securing personal and corporate data.

• CyberRisk™ Security Solutions Ltd. provides bespoke risk assessment and cyber security consulting services to satisfy corporations’ compliance and governance needs.

• Finjan also incubates up-and-coming technology startups pioneering a new generation of security technologies through its investment in Jerusalem Venture Partners (JVP) innovation funds.

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

• Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
• Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
• Strong IP position with composition of matter and method patents for antisense targets and manufacturing
• Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
• Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment

Learn More